Valby, Denmark, 2016-05-11 07:42 CEST (GLOBE NEWSWIRE) -- HIGHLIGHTS Revenue reached DKK 3,770 million in the first quarter of 2016 representing an increase of 6% both reported and in local currencies compared to the same period last year Total revenue have delivered a better performance than
Valby, Denmark, 2017-05-10 07:43 CEST (GLOBE NEWSWIRE) -- HIGHLIGHTS Revenue reached DKK 4,211 million in the first quarter of 2017 representing an increase of 12% compared to the same period last year Revenue in North America increased by 21% to DKK 2,437 million (21% in local currency) Revenue in
H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in clinical development by initiating clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. Lu AF11167 is a new compound inhibiting a
Den første FDA-godkendte månedlige, langtidsvirkende, injicerbare behandling til vedligeholdelsesbehandling af bipolar I lidelse I hos voksne 1,2 Den nye indikation for Abilify Maintena er baseret på et forsøg, der evaluerer præparatets effekt og sikkerhed til behandling af voksne patienter med
First FDA-approved, once-monthly, long-acting injectable for the maintenance monotherapy treatment of bipolar I disorder in adults 1,2 New indication for Abilify Maintena is based on studies evaluating efficacy and safety in adult patients with bipolar I disorder 1 Valby, Denmark and Tokyo, Japan,
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act. The list is based on reports received by H.
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act. The list is based on reports received by H.
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act. The list is based on reports received by H.
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act. The list is based on reports received by H.
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act. The list is based on reports received by H.
In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request.Please contact us here.